By treating mice with the messenger RNA (mRNA) encoding a bispecific antibody, rather than with the antibody itself, researchers from the German University of Mainz and Biontech AG have eliminated tumors in mice. In a direct comparison, the mRNA worked as well as the protein antibody did, and needed to be administered less often.
Transmissible endoplasmic reticulum stress (TERS) can spread from one cancer to another and convey resistance to many treatments, including nutrient starvation, the chemotherapy Taxol (paclitaxel) and the proteasome inhibitor Velcade (bortezomib, Takeda Pharmaceutical Co. Ltd.).
CHICAGO – With the firm establishment of immunotherapy, so far in the form of checkpoint blockade, as a pillar of cancer therapy, drug developers are finding themselves with an enviable problem right now: how to pick the most promising of many promising combination strategies to move forward in combination with PD-1 and PD-L1 blockers.
CHICAGO – Loxo Oncology Inc.'s announcement that it will seek tissue-agnostic approval for larotrectinib (LOXO-101) based on data that were presented at this year's ASCO meeting came just weeks after Keytruda (pembrolizumab, Merck & Co. Inc.) was approved for use in MSI-H/dMMR tumors regardless of tumor histology.
CHICAGO — Detailed genomic profiling is a sine qua non of precision medicine, and at tertiary cancer centers, the comprehensive profiling of tumors and matched germline DNA is becoming ever more routine.
Researchers have developed analogues of vancomycin with three independent and synergistic mechanisms of action. Developing antibiotics that overcome resistance often focuses on improving a drug's fit with its binding pocket, but much like in the development of antitumor drugs, bacteria can evolve resistance to such second-generation inhibitors as well.
